34 results about "Astragaloside IV" patented technology

The invention relates to the technical field of veterinary chemical drugs, and provides an application of a selenium-rich composition in a drug for preventing bone marrow suppression after chemotherapy of dogs, and the selenium-rich composition comprises nano-selenium-beta-glucan chelate and L-selenium-methyl selenocysteine, the mass ratio of the nano-selenium-beta-glucan chelate to the L-selenium-methyl selenocysteine is 1: (0.3-0.6), and the mass ratio of the nano-selenium-beta-glucan chelate to the L-selenium-methyl The molar ratio of the astragaloside IV to the cobamamide is (5 to 8): 1. Through the synergistic effect of the nano-selenium-beta-glucan chelate and the L-selenium-methyl selenocysteine and in combination with the loading technology of the silicon dioxide mesoporous carrier, the absorption rate of selenium is greatly improved.

The invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease as well as a preparation and application thereof, and belongs to the technical field of chronic obstructive pulmonary disease medicines. The traditional Chinese medicine composition consists of a qi tonifying component, a blood activating component and a phlegm reducing component, or consists of the qi tonifying component and the blood activating component, or consists of the qi tonifying component and the phlegm reducing component, wherein the qi-tonifying component is selected from any one or a combination of more of ginsenoside Rg1, ginsenoside Rb1, astragaloside and schizandrin; the blood activating component is selected from any one or combination of more of ligustrazine and ferulic acid; the phlegm reducing component is selected from any one or combination of more of glucosinolate and quercetin. The compatibility and combination of the medicines have obvious effects in the aspects of improving lung inflammatory response and inhibiting pathological remodeling of pulmonary blood vessels.

The invention belongs to the technical field of biomedical materials, and particularly relates to astragaloside-loaded conductive hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: uniformly mixing a methylacrylic anhydride gelatin aqueous solution with an organic solvent solution of astragaloside, and carrying out ultraviolet light cross-linking curing to form methylacrylic anhydride gelatin / astragaloside hydrogel; soaking the obtained hydrogel in hydrochloric acid containing a free radical initiator; then soaking and polymerizing in an aniline ethanol solution; and soaking and purifying to obtain the methylacrylic anhydride gelatin-polyaniline conductive hydrogel loaded with astragaloside. In-vitro experiments prove that the compound has a certain anti-inflammatory effect, can induce neural stem cells to be directionally differentiated into neurons and oligodendrocytes, and is beneficial to promoting nerve regeneration and myelin sheath formation; finally, in-vivo experiments prove that the composition can improve the athletic ability and tissue function recovery of SCI rats, and has a good application prospect.

The invention provides lactobacillus reuteri GY-18 and application thereof in increasing the content of astragaloside, and belongs to the technical field of microorganisms, fermentation and natural product biotransformation. The lactobacillus reuteri GY-18 capable of improving the content of astragaloside in a fermented astragalus membranaceus product is obtained through screening, the lactobacillus reuteri GY-18 is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number is CCTCC M 20252796, and the lactobacillus reuteri GY-18 can be used for improving the content of astragaloside in the fermented astragalus membranaceus product. The lactobacillus reuteri GY-18 can secrete acetylxylan esterase for promoting conversion of astragaloside into astragaloside IV, has efficient specificity on conversion of astragaloside into astragaloside IV, and is high in conversion capacity; according to the method, the content of astragaloside IV is remarkably increased within 24 hours in a semi-solid state fermentation mode, and the method has good practicability.

The invention relates to the technical field of medicines for treating intestinal ischemia-reperfusion injury, and discloses a medicine for treating intestinal ischemia-reperfusion injury and a preparation method thereof. Comprising 10 to 25 parts of rosmarinic acid, 5 to 15 parts of betaine, 3 to 10 parts of glutamine, 10 to 25 parts of salvianolic acid B, 5 to 15 parts of astragaloside, 3 to 10 parts of ginsenoside Rg1, 2 to 8 parts of curcumin, 5 to 12 parts of ophiopogon japonicus polysaccharide, 2 to 6 parts of notoginsenoside R1, 3 to 7 parts of total flavonoids of oldenlandia diffusa and 4 to 9 parts of angelica sinensis polysaccharide. The medicine disclosed by the invention can be used for relieving intestinal edema, repairing oxidative injury, clearing excessive ROS, improving SOD activity, blocking oxidative stress injury, inhibiting epithelial cell apoptosis, reducing intestinal permeability and maintaining mucous membrane integrity, and has an excellent treatment effect on intestinal ischemia reperfusion injury.

The invention discloses a heart-protecting granule identification and quality control method based on thin layer chromatography, and belongs to the technical field of medicine detection. The thin-layer chromatography identification method comprises the following steps: identifying astragalus membranaceus by taking astragaloside as a reference substance, identifying wine-treated rhubarb by taking chrysophanol and emodin as reference substances, identifying leech by taking a leech medicinal material as a reference substance, identifying liquorice by taking liquiritin and a liquorice medicinal material as reference substances, and identifying radix rehmanniae by taking catalpol as a reference substance. And identifying salvia miltiorrhiza by taking salvianolic acid B and salvia miltiorrhiza medicinal materials as reference substances, and identifying fructus aurantii by taking naringin and neohesperidin as reference substances. By establishing the thin-layer chromatography identification method of the heart-protecting granules, an exclusive developing solvent and a developing mode are adopted, accurate identification is achieved according to the characteristics of spot colors, fluorescence characteristics and the like of corresponding positions of a test substance chromatography, a reference substance and a reference medicinal material chromatography, and the method is easy and convenient to operate, low in detection cost and high in repeatability and specificity; and quality control can be effectively carried out in the production process of the heart-protecting granules.

This invention discloses a thin-layer chromatography method for identifying health tonics, comprising: preparing a test sample solution; preparing a reference herbal solution; preparing a reference standard solution; taking 1-2 μl of each of the above three solutions and spotting them separately in strip form on the same high-efficiency silica gel G thin-layer plate; using the upper layer solution of n-butanol-ethyl acetate-water in a volume ratio of 1-8:0.1-1:1-7 as the developing solvent; developing to approximately 15 cm; removing, air-drying, spraying with 10% sulfuric acid ethanol solution, and heating at 105°C until the spots are clearly visible; and examining under sunlight and ultraviolet light (365 nm). This invention can effectively solve the problem of astragaloside A and ginsenoside R in health tonics through a simple processing method. f The problem of mutual interference. This provides a basis for the identification of health wines and a reference for product quality control.

The invention belongs to the technical field of medicines for treating polycystic ovarian syndrome, and particularly relates to application of astragaloside IV and a compound thereof in preparation of a medicine for treating polycystic ovarian syndrome and the medicine. The compound is prepared from the following raw materials: mannitol, vitamin B3 and vitamin B9, wherein the mass ratio of the mannitol to the vitamin B3 to the vitamin B9 is (0.5-1): (0.5-1): 1; the mass ratio of the astragaloside IV to the compound is 1: (2-4). The mannitol, the vitamin B3 and the vitamin B9 are used for activating a PPAR gamma channel, increasing the relative expression quantity of PPAR gamma and inhibiting proliferation of human ovarian granular cells. And the mannitol, the vitamin B3, the vitamin B9 and the astragaloside IV are mixed for use, so that the effect is optimal.

The invention belongs to the technical field of biology, and particularly relates to application of astragaloside in regulation of parthenogenetic activation embryo development. According to the method disclosed by the invention, the maturation rate of the oocytes can be obviously improved by adding substances such as astragaloside into the sheep oocyte in-vitro maturation liquid. The preparation method comprises the following steps: firstly, respectively adding lycopene, astragaloside, isoliquiritigenin, forsythin and baicalein into an oocyte maturation solution, and screening out the optimal dosage of each additive according to the first polar body discharge rate, the cleavage rate and the blastocyst rate; and finally, adding an additive combination into the oocyte maturation liquid according to the screened optimal dosage, detecting the first polar body discharge rate, the cleavage rate and the blastocyst rate to determine an optimal composition, and detecting the levels of ROS, GSH, mitochondrial membrane potential, oxidative stress and apoptosis related genes of the optimal composition to further determine the application effect of the composition.

The invention discloses an interpenetrating polymer network-based hydrogel material and a preparation method thereof, and the preparation method comprises the following steps: sequentially adding an acellular extracellular matrix solution, astragaloside IV, polyethylene glycol diacrylate and a photoinitiator into a polyvinyl alcohol solution, and uniformly mixing; refrigerating the mixture overnight, and then carrying out cross-linking reaction under ultraviolet light; the cross-linked hydrogel is sequentially subjected to CaCl2 solution soaking, NaOH solution soaking and multiple times of freezing and thawing cycle treatment. The astragaloside IV is used as a part of a hydrogel matrix, and the hydrogel with excellent mechanical properties and biological activity is formed through the synergistic effect of the astragaloside IV, the polyvinyl alcohol and the acellular extracellular matrix. The interpenetrating polymer network hydrogel based on the polyvinyl alcohol and the acellular extracellular matrix can be applied to preparation of motor system tissue repair or replacement materials, and is particularly applied to repair and replacement of bone, cartilage or ligament defects and promotion of tissue regeneration.

The invention belongs to the field of medicines, and particularly relates to a pharmaceutical composition and an analysis method thereof, and the pharmaceutical composition comprises the following components: 1-30 parts by weight of astragaloside and 10-2000 parts by weight of 6-gingerol.

The invention discloses an application of a compound composition containing astragaloside IV in preparation of a medicine for resisting plateau fatigue, and the compound composition containing astragaloside IV is prepared from the following raw materials in parts by weight: 500 to 2000 parts of astragaloside IV, 5000 to 20000 parts of ginsenoside Rg1, 2 to 5 parts of vitamin D3 and 30000 to 150000 parts of puerarin. Animal experiments prove that the compound composition can relieve plateau exercise fatigue, improve the hypoxia tolerance, exercise fatigue resistance and oxidative stress resistance of a body and improve the comprehensive exercise performance of the body. According to the invention, the defect of single-component efficacy is overcome, a compound preparation is designed in a targeted manner, an innovative and feasible compound combination is provided, and a new scheme is provided for promoting athletic performance under plateau hypoxia.

The invention discloses a multi-index quality control method of Naoxinan capsules, and relates to the technical field of medical drugs, the method adopts a high performance liquid chromatography to establish a wavelength characteristic spectrum for detection, and the method specifically comprises the following steps: detecting a characteristic spectrum 1 under the wavelength of 260nm: taking a puerarin reference substance peak (marked as 1 (S)) as a reference, and detecting the characteristic spectrum 2 under the wavelength of 260nm; five characteristic peaks are required to be presented in the chromatogram of the test sample, and the similarity between the retention time of the five characteristic peaks and the contrast characteristic chromatogram is greater than or equal to 0.90; and / or detecting a characteristic spectrum 2 under the wavelength of 320nm: by taking a puerarin reference substance peak (marked as 1 (S)) as a reference, requiring that five characteristic peaks appear in a chromatogram of the test sample, and the similarity between the retention time of the five characteristic peaks and the contrast characteristic spectrum is greater than or equal to 0.90. According to the invention, five active ingredients such as flavonoids (puerarin), saponins (astragaloside) and phenolic acids (tanshinol) are covered through a wavelength characteristic spectrum (260nm and / or 320nm).

The invention belongs to the technical field of biology, and particularly relates to application of lycopene in sheep oocyte in-vitro culture. It is determined that the maturation rate of the oocytes can be remarkably increased by adding the lycopene and astragaloside composition into the sheep oocyte in-vitro maturation liquid. The preparation method comprises the following steps: firstly, respectively adding lycopene, astragaloside, isoliquiritigenin, forsythin and baicalein into an oocyte maturation solution, and screening out the optimal dosage of each additive according to the first polar body discharge rate, the cleavage rate and the blastocyst rate; and finally, adding an additive combination into the oocyte maturation liquid according to the screened optimal dosage, detecting the first polar body discharge rate, the cleavage rate and the blastocyst rate to determine an optimal composition, and detecting the levels of ROS, GSH, mitochondrial membrane potential, oxidative stress and apoptosis related genes of the optimal composition to further determine the application effect of the composition.

The application discloses a culture medium for improving in-vitro aging of oocytes after ovulation and application thereof. The culture medium is prepared by adding 0.1-30 muM of astragaloside IV into an oocyte culture solution. The culture medium is safe, non-toxic and free of side effects, can reduce the oocyte fragmentation rate, active oxygen level and abnormal spindle rate of the oocytes after 24 hours of in-vitro culture, can significantly improve the mitochondrial membrane potential, in-vitro sperm binding capacity, in-vitro fertilization pronucleus rate and cleavage rate of the mature oocytes after 24 hours of in-vitro culture, and can improve the quality of the late embryos. The application of the culture medium provides favorable support for assisted reproductive technology, and has a good application prospect.

The invention relates to a pharmaceutical composition with an effect of improving blood-brain barrier injury after cerebral infarction thrombolysis. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-100 parts of astragaloside, 0.25-25 parts of tanshinol and 1-100 parts of notoginsenoside R1.

The present application relates to a new medical use of Astragaloside IV, and particularly relates to the use of Astragaloside IV in the preparation of a medicine for promoting the osteogenic differentiation of BMSCs of a patient with congenital scoliosis. The present application discloses that Astragaloside IV can specifically up-regulate the expression of WISP2, and then activate the Wnt / β-catenin pathway, significantly improve the alkaline phosphatase activity, mineralization capacity and osteogenic related gene expression of CS-BMSCs. Through cell induction, animal implantation and targeted sustained-release preparation and other experimental means, the present application confirms the safety and effectiveness of Astragaloside IV in repairing CS-related osteoporosis, and has a good application prospect.

The invention relates to the technical field of natural organic chemistry, in particular to a method for obtaining astragaloside IV by using citrus fermentation broth, which utilizes organic acid, enzymes and fermentation metabolites produced by natural fermentation of citrus to destroy cell wall structures of astragalus membranaceus medicinal materials, reduce intermolecular forces and improve the yield of astragaloside IV. Therefore, fat-soluble macromolecular astragaloside is promoted to be dissolved into a water phase from the interior of a cell. The method mainly comprises the following three stages: 1, preparing citrus fermentation liquor; 2, fermenting the astragalus membranaceus by utilizing the citrus fermentation liquor; and 3, extracting and purifying. Compared with traditional water extraction or alcohol extraction, the method has the advantages that natural and renewable oranges are utilized, conditions are mild, damage to heat-sensitive components is reduced, the dissolution rate and extraction efficiency of astragaloside are improved, use of organic solvents is reduced, and the composition prepared from the astragaloside prepared through the method is beneficial to delaying cell senescence of mammals.

The application belongs to the technical field of biological medicine, and provides application of astragaloside IV in preparation of a medicine for treating advanced ovarian cancer. The application analyzes and studies a targeting effect of AS-IV on CD276, determines a molecular mode of covalent combination of AS-IV and CD276, identifies a molecular mechanism of combination of AS-IV and CD276 through an E3 ubiquitin ligase and activation of an mTORC1 pathway of NK cells, and determines application potential of AS-IV in enhancement of NK cell anti-tumor immunity in preparation of an OC immunotherapy medicine.

The invention discloses a process for preparing astragaloside through multi-step enzymolysis. According to the invention, windowing control is carried out around the astragaloside wall opening, releasing, transferring and grading process through a multi-step enzymolysis, segmented ultrasonic permeation / strengthening and ultrafiltration and nanofiltration series preparation process. The astragaloside yield and the crude product purity are obviously improved.

The invention belongs to the technical field of traditional Chinese medicine processing, and particularly relates to an astragaloside extraction method. The active ingredient astragaloside IV of astragalus membranaceus is directly extracted by using a natural deep-eutectic solvent extraction method, betaine and lactic acid are mixed and dissolved according to the mass ratio of 5: (25-35) to obtain a lactic acid-betaine deep-eutectic solvent, astragalus membranaceus powder is added, extraction is performed through specific process parameters, the content of astragaloside IV in the extracted product is up to 4.2 mg / g, and the content of astragaloside IV in the extracted product is up to 4.2 mg / g. Compared with a traditional ethanol extraction method, the extraction rate is increased by 25%. The method has the advantages of simple and rapid process flow and easiness in industrial production.

The invention relates to a method for extracting astragaloside, which belongs to the field of natural medicines, and comprises the following steps of: crushing astragalus membranaceus, and performing reflux extraction in an alkaline solvent, the pH range of the alkaline environment is 9-13, and the pH range of the alkaline condition is regulated by using alkaline reagents KOH, NaOH and Na2CO3.

The invention relates to the technical field of pharmaceutical preparations, in particular to an astragaloside nano preparation for treating hepatitis B and a preparation method thereof. The astragaloside nano preparation for treating hepatitis B comprises astragaloside and auxiliary materials, wherein the auxiliary materials comprise at least one of polyoxyethylene polyoxypropylene ether triblock copolymer, phospholipid, albumin and casein. The auxiliary materials and astragaloside can be compounded to form an astragaloside nano preparation with good water solubility and high bioavailability, and hepatitis B can be safely and effectively treated.

The invention relates to a B cell inhibitor and application thereof in preparation of drugs for treating xerophthalmia. The present invention relates to a B cell activity inhibitor selected from the group consisting of formononetin; formononin; astragaloside IV; total flavonoids of an astragalus extract; the components are astragaloside IV and formononetin; astragaloside IV and formononin; the composition is prepared from astragaloside I, astragaloside IV, formononin and formononetin. Compared with the side effect of cyclosporine in the prior art (which is within the renal toxicity of 1 / 3 of a patient who takes the medicine), the astragalus extract general flavone has the effect of inhibiting the activity of B cells so as to inhibit humoral immunity. On the basis of the research on the disease mechanism of pSS, the specific astragalus membranaceus extract general flavone which can be used as a medicine for administration and a medicine for instillation is developed.

The invention discloses a method for preparing astragaloside IV by utilizing microbial conversion, and particularly relates to a method for improving the content of astragaloside IV in an astragalus membranaceus water extraction concentrated solution by utilizing bacillus subtilis and taking the astragalus membranaceus water extraction concentrated solution as a substrate. The obtained astragaloside is relatively high in purity, the operation is simple, no pollution is caused, and the reaction conditions are mild.

This invention relates to a method for constructing and applying an HPLC fingerprint of a traditional Chinese medicine granule for invigorating qi and promoting blood circulation, belonging to the field of biomedical technology. This invention provides a method for establishing an HPLC fingerprint of the traditional Chinese medicine granule Qishen Jianxin Granules and its application. The application includes using HPLC fingerprinting with isoflavone glucoside, glycyrrhizin, and ammonium glycyrrhizate as references to achieve quality control of the Qishen Jianxin Granules, and quantifying key components by determining the content of astragaloside A. This invention provides a traditional Chinese medicine granule with definite efficacy, strict quality control, and stable controllability, and its quality control method. It achieves overall characteristic control through HPLC fingerprinting and quantifies key components through the determination of astragaloside A content, providing dual assurance of preparation quality and efficacy. It is highly practical and has good industrialization and promotion value.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to a traditional Chinese medicine extract with gene repair and cell repair effects and a preparation process thereof, and the traditional Chinese medicine extract is prepared from astragaloside, fisetin, HA-PLGA, FA-PEG-CRGDK and other raw materials. By constructing a core-shell structure delivery system, sequential release of active ingredients is realized, ROS is quickly cleared, and an Nrf2 pathway is activated to promote DNA damage repair. The preparation process comprises the steps of construction of an inner core drug-loading system, assembly of a core-shell structure, coating of a phospholipid membrane, freeze drying and the like. The application can improve the utilization rate of active ingredients, enhance stability and targeting, is suitable for DNA damage repair caused by oxidative stress, solves the problem of poor synergistic effect of a traditional Chinese medicine compound preparation, reduces the production cost, and has wide application prospects.

The invention discloses a method for detecting astragaloside IV in kernel-bighead atractylodes rhizome stomach-invigorating granules. The method for detecting the astragaloside IV in the kernel-bighead atractylodes rhizome stomach-invigorating granules comprises the following steps: step 1, preparing a reference substance solution; step 2, preparing a test solution; and step 3, respectively and precisely sucking the reference substance solution and the test solution, injecting into a liquid chromatograph, and determining by an evaporative light-scattering detector. The detection method established by the invention is rapid and accurate in analysis, free from interference of negative samples, strong in specificity and good in reproducibility and stability, the peak pattern of the chromatographic peak of the obtained chromatogram is relatively good, and the quality of the kernel-bighead atractylodes rhizome stomach-invigorating granules can be objectively evaluated.

The present application relates to the field of targeted drugs, and discloses a drug self-assembly system for treating chronic heart failure, and a preparation method and application thereof, the drug self-assembly system comprising: a drug active component (including astragaloside and tanshinone II A), a phosphatidylated triphenylphosphine compound and a biomimetic membrane (a product obtained after mixing of macrophage membrane fragments and myocardial cell membrane fragments); the phosphatidylated triphenylphosphine compound is embedded on the surface of nanoparticles self-assembled by the drug active component, and the biomimetic membrane is wrapped on the outer layer of the modified nanoparticles; the encapsulation rate of the drug active component in the drug self-assembly system is 80-95 wt%. The drug self-assembly system provided by the present application improves the encapsulation rate of the drug active component and can realize efficient drug delivery, has good stability and high safety, has low preparation process cost, and has good batch production and clinical transformation prospects.

The present invention belongs to the field of chemical medicine, and particularly relates to a combined drug of astragaloside IV, chlorogenic acid and scutellarin for treating chronic cerebral ischemia. The present invention provides the use of the combined use of astragaloside IV, chlorogenic acid and scutellarin in the preparation of a drug for preventing and / or treating chronic cerebral ischemia. In addition, calycosin can also be used as an additional component to be combined with the above three components to prepare a drug for preventing and / or treating chronic cerebral ischemia. The drug of the present invention can have synergistic effects, is used for treating chronic cerebral ischemia, and produces good therapeutic effects, providing a new option for the clinical treatment of chronic cerebral ischemia and having good application prospects.